|
Effects | Compounds | Microorganism | Dose and effect | References |
|
Antibacterial effects | 1-Methoxyficifolinol, licorisoflavan A, and 6,8-diprenylgenistein | Streptococcus mutans | Showed bactericidal effects at the concentration of ≥4 μg/ml | [164] |
Flavonoid of G. uralensis extracts | Streptococcus mutans and Candida albicans | The inhibition zones of S. mutans and C. albicans increased in order: 50 μg/ml < 100 μg/ml < 150 μg/ml < 200 μg/ml | [165] |
Licoricidin and glabridin | Streptococcus mutans | Licoricidin had an MIC of 6.25 μg/mL and an MBC between 6.25 and 25 μg/mL; glabridin showed an MIC from 6.25 to 12.5 μg/mL and an MBC between 6.25 and 25 μg/mL against one reference (ATCC 25175) and four clinical (12A, 33A, INB, and T8) strains of S. mutans | [166] |
Flavonoid-rich extract of G. glabra | Helicobacter pylori | At minimum inhibitory concentration (MIC) of 100 μg/ml | [167] |
Flavonoids of G. glabra, namely, licoricone, glycyrin, and glyzarin | Acinetobacter baumannii | Significantly reduced quorum sensing regulated virulence factors of A. baumannii at 0.5 mg/ml | [168] |
Isoliquiritigenin and liquiritigenin | MRSA | MIC of both components exhibited significant anti-MRSA activity (50–100 μg/ml) against clinical isolates of MRSA | [169] |
Licochalcone A | Bacillus subtilis | The vegetative cell growth of B. subtilis was inhibited in a concentration-dependent manner and was completely prevented by 3 μg/ml | [170] |
Licochalcone A | Candida albicans | Reduced C. albicans biofilm growth at 625 μM in vitro; and mice treated with licochalcone A exhibited a markable reduction in total photon flux and CFU/ml/mg of tongue tissue sample | [171] |
Nisin/glabridin, nisin/licoricidin, and nisin/licochalcone A | Enterococcus faecalis | Efficiently restrained the growth of E. faecalis, with MICs ranging from 6.25 to 25 μg/mL | [172] |
6-Aldehydo-isoophiopogonone and liquiritigenin | Multidrug-resistant human bacterial Staphylococcus aureus | 6-Aldehydo-isoophiopogonone and liquiritigenin showed activity against S. aureus with a zone inhibition of 10 ± 0.2 mm and 10 ± 0.3 mm | [173] |
Glabridin | Amphotericin B resistant Candida albicans | At an MIC of 31.25–250 μg/mL | [174] |
Liquiritin | Phytophthora capsici | Suppressed the P. capsici mycelial growth with EC50 of 658.4 mg/L and caused P. capsici sporangia to shrink and collapse | [175] |
Antiviral effects | Echinantin and isoliquiritigenin | Influenza A viruses | Showed strong inhibitory effects on various neuraminidases from influenza viral strains, H1N1, H9N2, novel H1N1 (WT), and oseltamivir-resistant novel H1N1 (H274Y) expressed in 293T cells | [176] |
Licocoumarone, glyasperin C, 2′-methoxyisoliquiritigenin, glycyrin, licoflavonol, and glyasperin D | Rotaviruses, specially G5P [7] and G8P [7] | The 50% effective inhibitory concentrations (EC50) of the six compounds were 18.7–69.5 μM against G5P [7] and 14.7–88.1 μM against G8P [7] | [177] |
Quercetin of G. uralensis | Herpes simplex virus-1 (HSV-1) | Showed 50% decrease for 10 μg/ml quercetin and 90% decrease for 30 μg/ml of quercetin in plaque formation in Vero cells when incubated with infected cell lysates treated with quercetin; dose-dependently suppressed HSV-1 infection in Raw 264.7 cells | [178] |
Kanzonol Y | Dengue virus (DENV) | Exhibited anti-dengue-virus activity due to the outstanding docking properties with DENV protease, DENV RNA-dependent RNA polymerase, and DENV envelope protein | [179] |
Isobavachalcone | Porcine reproductive and respiratory syndrome virus (PRRSV) | Had potential anti-PRRSV activity and inhibited PRRSV replication at the postentry stage of PRRSV infection | [180] |
Antiprotozoan effects | Licochalcone A | Chloroquine-susceptible (3D7) and chloroquine-resistant (Ddz) strains of Plasmodium falciparum | Had potent antiplasmodial efficacy against chloroquine-susceptible (3D7) and chloroquine-resistant (Ddz) strains of Plasmodium falciparum in vitro | [181] |
|